Vandetanib Versus Gefitinib in Patients With Advanced Non―Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II StudyNATALE, Ronald B; BODKIN, David; RANSON, Malcolm et al.Journal of clinical oncology. 2009, Vol 27, Num 15, pp 2523-2529, issn 0732-183X, 7 p.Article

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung CancerHANRAHAN, Emer O; RYAN, Anderson J; MANN, Helen et al.Clinical cancer research (Print). 2009, Vol 15, Num 10, pp 3600-3609, issn 1078-0432, 10 p.Article

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancerHEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, issn 0732-183X, 8 p.Article